FONT-SIZE Plus   Neg

Scania Q1 Profit Declines - Quick Facts

Scania (SVKBY.PK) said its first-quarter profit dropped to SEK 1.79 billion or SEK 2.24 per share from last year's SEK 2.51 billion or SEK 3.14 per share.

Net sales were down 3 percent to SEK 20.13 billion from SEK 20.69 billion in the prior-year quarter. Total deliveries decreased 15 percent year-over-year to 16,238 vehicles. Order bookings declined 19 percent to 15,809 from a year ago.

Lower vehicle deliveries and lower capacity utilisation pulled down earnings, as did higher costs for future-related projects, the company noted.

Leif Östling, President and CEO, said,

"...A more favourable market mix had a positive effect, as deliveries in Brazil were supported by some 2,000 Euro 3- vehicles during the first quarter. Total deliveries fell due to a deceleration in demand in late 2011. Scania has adjusted its production rate to the current level of demand. Overall order bookings for trucks during the first quarter of 2012 were in line with the end of last year..."

Further, the Board of Directors proposed a dividend of SEK 5.00 per share, same as last year, for the financial year 2011, with 9 May 2012 as the record date.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Visa Inc. (V) on Monday reported an increase in profit for the fourth quarter, as revenues jumped driven largely by increase in customer spending and inclusion of Europe business. Earnings and revenues trumped Wall Street expectations. Foster City, California-based Visa's fourth-quarter profit rose... As Sony Corp. prepares to launch the new PlayStation 4 Pro gaming console on November 10, several new games that are compatible with the console have also been confirmed for launch. Game developers are readying to provide PlayStation 4 Pro support for many games on PS4. Shares of Advaxis Inc. dropped more than 13 percent in pre-market activity before paring losses to just more than 5 percent after the company said that it was not able to complete the second stage of the Phase 2 GOG-0265 trial as designed due to a clinical hold that affected its clinical development programs last year.
comments powered by Disqus
Follow RTT